Ligand Pharmaceuticals (LGND) Declines More Than Market: Some Information for Investors
https://www.zacks.com/stock/news/2241058/ligand-pharmaceuticals-lgnd-declines-more-than-market-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2241058
Mar 14, 2024 - Ligand Pharmaceuticals (LGND) reachead $71.93 at the closing of the latest trading day, reflecting a -1.14% change compared to its last close.
0
Ligand Pharmaceuticals (LGND) Stock Dips While Market Gains: Key Facts
https://www.zacks.com/stock/news/2251479/ligand-pharmaceuticals-lgnd-stock-dips-while-market-gains-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2251479
Apr 05, 2024 - Ligand Pharmaceuticals (LGND) closed at $77.96 in the latest trading session, marking a -0.03% move from the prior day.
0
Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?
https://www.zacks.com/stock/news/2259547/will-alkermes-alks-proprietary-drugs-aid-amid-competition?cid=CS-ZC-FT-analyst_blog|zer_report_update-2259547
Apr 22, 2024 - Alkermes (ALKS) expects its set of proprietary products, Vivitrol, Aristada and Lybalvi, to generate incremental sales and combat stiff competition in 2024.
0
Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study
https://www.zacks.com/stock/news/2260438/sanofi-sny-rilzabrutinib-shows-benefit-in-blood-disorder-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2260438
Apr 23, 2024 - Sanofi's (SNY) BTK inhibitor, rilzabrutinib, demonstrates durable platelet response in the phase III LUNA 3 study in adult patients with immune thrombocytopenia.
0
Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study
https://www.zacks.com/stock/news/2260461/corcept-cort-posts-positive-data-from-cushing-s-syndrome-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2260461
Apr 23, 2024 - Corcept (CORT) reports positive data from the open-label portion of the phase III GRACE study evaluating relacorilant for treating patients with Cushing's syndrome.
0
Ligand Pharmaceuticals (LGND) Advances While Market Declines: Some Information for Investors
https://www.zacks.com/stock/news/2221375/ligand-pharmaceuticals-lgnd-advances-while-market-declines-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2221375
Feb 05, 2024 - In the closing of the recent trading day, Ligand Pharmaceuticals (LGND) stood at $74.72, denoting a +0.24% change from the preceding trading day.
0
Ligand (LGND) Is Considered a Good Investment by Brokers: Is That True?
https://www.zacks.com/stock/news/2242754/ligand-lgnd-is-considered-a-good-investment-by-brokers-is-that-true?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2242754
Mar 19, 2024 - According to the average brokerage recommendation (ABR), one should invest in Ligand (LGND). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
0
EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia
https://www.zacks.com/stock/news/2250019/ema-accepts-rocket-rckt-gene-therapy-filing-for-fanconi-anemia?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2250019
Apr 03, 2024 - The EMA accepts Rocket's (RCKT) regulatory submission seeking approval for RP-L102, a gene therapy for a rare genetic disorder called fanconi anemia that affects the bone marrow.
0
Vanda (VNDA) Up on FDA Nod for Fanapt in Bipolar I Disorder
https://www.zacks.com/stock/news/2249959/vanda-vnda-up-on-fda-nod-for-fanapt-in-bipolar-i-disorder?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2249959
Apr 03, 2024 - Vanda (VNDA) announces the FDA's approval of Fanapt for the acute treatment of bipolar I disorder in adults. The stock rises 30.4%.
0
Amarin (AMRN) Up 7% on Intellectual Property Wins in Europe
https://www.zacks.com/stock/news/2250719/amarin-amrn-up-7-on-intellectual-property-wins-in-europe?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2250719
Apr 04, 2024 - Amarin (AMRN) secures a new patent for Vazkepa in Europe, which extends its exclusivity for eight more years. It achieves success in defending another patent on the drug against third parties.
0
Pages: 12
Page 1